[Regulatory] state board actions worth reading if you use a compounder
state board actions worth reading if you use a compounder. Not a hot take, just something I have not seen said plainly here.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
Removed the staff name.
This is the distinction the whole board runs on. Everything else follows from it.
shortage status changes and the whole arrangement changes with it
Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
the shortage list is the whole legal hinge and people skip it
What did the intake actually ask you?